The emergence of GLP-1 receptor agonists has revolutionized treatment for obesity and type 2 diabetes, achieving weight loss comparable to bariatric surgery in many patients.
Despite their efficacy, GLP-1 therapies show diminished weight-lowering effects in those with both obesity and type 2 diabetes, highlighting a significant area for further research.
Targeting energy expenditure remains a crucial strategy not yet fully addressed by current obesity treatments, with historical methods demonstrating both potential and safety challenges.
The glucagon receptor agonism approach shows promise for enhancing catabolic metabolism, but linked cardiovascular concerns necessitate careful evaluation in therapeutic development.
#glp-1-receptor-agonists #type-2-diabetes #obesity-treatment #energy-expenditure #catabolic-metabolism
Collection
[
|
...
]